Six Pivotal Trial Readouts To Look Out For In Q4

 
• By Ayisha Sharma

With help from Biomedtracker, Scrip takes a look at six drug candidates expecting pivotal data by the end of the year. The assets span a range of therapeutic areas, from ophthalmology to neurology, and are poised to become market firsts, rivals to dominant products or win important label expansions.  

Arrow shooting through complex maze
These Six Drug Candidates Are Approaching The End Of The Pipeline • Source: Shutterstock

Roche Holding AG and partners Chugai Pharmaceutical Co., Ltd. and MorphoSys AG are anticipating data from their IgG1 antibody for Alzheimer’s disease (AD), gantenerumab.

The candidate targets amyloid beta, an approach that saw a recent resurgence of confidence after rival Eisai Co., Ltd. and Biogen, Inc.’s lecanemab demonstrated slowdown of cognitive decline in its confirmatory trial following the disappointment surrounding their first-to-market product Aduhelm (aducanumab)

More from Clinical Trials

More from R&D